# Nitrosourea derivatives having anti tumour and anti bacterial activity.

## Abstract
Nitrosourea derivatives represented by the formula I

## Claims
CLAIMS 1. A derivative of nitrosourea represented by the formula I EMI27.1 wherein R1 is hydroxy and R2 isEMI27.2 or RI isEMI27.3 and R2 is hydroxy, and m and n each denote 0 or an integer of from 1 to 4, with the proviso that RI is notEMI27.4 and R2 is not hydroxy when m and n are both 0. 2. A derivative according to claim 1, wherein RI isEMI27.5 R2 is hydroxy, m is 0 and n is an integer of from 1 to 4. 3. A derivative according to claim 1, wherein RI is hydroxy, R2 isEMI27.6 m is O or an integer of from 1 to 4 and n is O. 4. A derivative according to claim 2, which is 2 methyl 2 3 2 chloroethyl 3 nitrosoureido 1,3propanediol 2 ethyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol 2 propyl 2 3 2 chloroethyl 3 nitrosoureidb3 1,3 propanediol or 2 butyl 2 t3 2 chloroethyl 3 nitrosoureido 1,3 propanediol. 5. A derivative according to claim 3, which is 3 3 2 chloroethyl 3 nitrosoureido 1,2 propanediol 3 3 2 chloroethyl 3 nitrosoureido 1,2 butanediol 3 3 2 chloroethyl 3 nitrosoureido 1,2 pentanediol 3 3 2 chloroethyl 3 nitrosoureido 1,2 hexanediol or 3 3 2 chloroethyl 3 nitrosoureido 3 1, 2 heptanediol. 6. A process for preparing a derivative of nitrosourea represented by the formula I as defined in claim 1, which process comprises reacting an amino alcohol represented by the formula II EMI28.1 wherein R1 is hydroxy and R2 is amino or R1 is amino and R2 is hydroxy, and m and n are each 0 or an integer of from 1 to 4, providing that RI1 is not amino and R2, is not hydroxy when m and n are both O, with chloroethyl isocyanate to prepare an intermediate compound represented by the formula IV EMI28.2 wherein R1 is hydroxy and R2,1 is NHCONHCH2 CH2Cl or R1 is NHCONHCH2CH2Cl and R2,,is hydroxy, and m and n are eachO or an integer of from 1 to 4, providing that R1 is not NHCONHCH2 CH2Cl and R2 is not hydroxy when m and n are both 0, and reacting the intermediate compound of Formula IV with a nitrous acid. 7. A process for preparing a derivative of nitrosourea represented by the formula I as defined in claim 1, which process comprises reacting an aminoalcohol represented by the formula II as defined in claim 6 with N 2 chloroethyl N nitrosocarbamylazide or p nitrophenyl N 2 chloroethyl N nitrosocarbamate. 8. A pharmaceutical composition comprising as active ingredient a derivative of nitrosourea represented by the formula I as defined in claim 1, together with a pharmaceutically acceptable carrier and or adjuvant. 9. A pharmaceutical composition according to claim 8 in unit dosage form. 10. A compound of the formula IV as defined in claim 6.

## Description
DESCRIPTION NITROSOUREA DERIVATIVES HAVING ANTI TUMOR AND ANTI BACTERIAL ACTIVITY The present invention relates to nitrosourea derivatives, their preparation and pharmaceutical compositions containing them. Many halogenated alkylnitrosoureas are known.Amongst those which are well known are 1,3 bis 2 chloroethyl l nitrosourea hereinafter referred to asBCNU , 1 2 chloroethyl 3 cyclobexyl l nitrosourea hereinafter referred to as CCNU and l 2 chloroethyl 3 4 methylcyclohexyl l nitrosourea hereinafter referred to as Me CCNU . However, since the above mentioned compounds are oil soluble, they are administered after dissolution in ethanol and accordingly, the administration of every one of them presses a burden on the patients to whom the compound is administered as well as injures the bone marrow, lymphatic gland, kidney, lung, liver and gastrointestinal system. The present invention is concerned with new derivatives of nitrosourea which are soluble in water and retain the useful properties of the known derivatives of nitrosourea while not showing the undesirable side effects mentioned above. Accordingly, the present invention provides a derivative of nitrosourea represented by the formula I EMI1.1 wherein R1 is hydroxy and R2 isEMI2.1 or R1 isEMI2.2 and R2 is hydroxy, and m and n each denote 0 or an integer of 1 to 4 providing that R1 is notEMI2.3 andR2 is not hydroxy when m and n are both 0. In a second aspect of the present invention, there is provided a process for preparing a derivative of nitrosourea represented by the formula I EMI2.4 wherein R1, R2, m and n are defined in the above, comprising reacting an amino alcohol represented by the formula II EMI2.5 wherein R1 is hydroxy and R2 is amino or R11 is amino and R2 is hydroxy, and m and n each 0 or an integer of 1 to 4 providing that R1 is no ami no and R2 is not hydroxy when m and n are 0, with a chloroethyl isocyanate to prepare an intermediate compound represented by the formula IV EMI2.6 wherein R1 is hydroxy and R2 is NHCONHCH2CH2Cl or R1 is NHCONHCH2CH2Cl and R2 is hydroxy, and m and n are each 0 or an integer of to 4 providing that R1 is not NHCONHCH2CH2Cl andR2 is not hydroxy when m and n are 0, and reacting the intermediate compound thus prepared with a nitrous acid. In a third aspect of the present invention, there is provided a process for preparing a derivative of nitrosourea represented by the formula I EMI3.1 wherein R1, R2, m and n are defined in the above, comprising reacting an amino alcohol represented by the formula II EMI3.2 wherein R1 , R2 , m and n are defined in the above, with N 2 chloroethyl N nitrosocarbamylazide or p nitrophenyl x 2 chloroethyl N nitrosocarbamate. In the fourth aspect of the present invention, there is provided a pharr.aceutical composition containing a derivative of nitrosourea represented by the formula I EMI3.3 wherein R1, R2, m and n are defined in the above, and a pharma ceutically acceptable carrier. The novel compounds according to the present invention are derivatives of nitrosourea hereinafter referred to as the present compounds represented by the formula I EMI4.1 wherein R1 is hydroxy and R2 isEMI4.2 or R1 isEMI4.3 and R2 is hydroxy, and m and n denote respectively an integer of 0 to 4 providing that R1 is notEMI4.4 andR2 is not hydroxy when rr and n are 0. The present compounds represented by the formula I include the following compounds 2 Methyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol,EMI4.5 2 Ethyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol,EMI4.6 2 Propyl 2 3 2 chlorethyl 3 nitrosoureido 1,3 propanediol,EMI5.1 2 Butyl 2 t3 2 chloroethyl 3 nitrosoureido lt3 propanediol, EMI5.2 3 3 2 Chloroethyl 3 nitrosoureido 1,2 propanediol, EMI5.3 3 3 2 Chloroethyl 3 nitrosoureido 1,2 butanediol,EMI5.4 3 3 2 Chloroethyl 3 nitrosoureido 1,2 pentanediol,EMI5.5 3 3 2 Chloroethyl 3 nitrosoureido 1, 2 hexanediol, EMI6.1 3 3 2 Chloroethyl 3 nitrosoureido 1,2 heptanediol.EMI6.2 The present compounds have excellent pharmacological activities such as anti tumour and anti bacterial activities and are pharmacologically safe. Accordingly, the present compounds are important compounds as an active ingredient of a pharmaceutical composition in treating various tumours and infections. The present compounds are prepared ES follows An amino alcohol represented by the formula II EMI6.3 wherein R1 is a hydroxy group and R2 is an amino group or R1 is an amino group and R2 is a hydroxy group, and m and n are respectively an integer of 0 to 4 providing that R1 is not amino group and R2 is not a hydroxy group when m and n are 0, is brought into reaction with chloroethyl isocyanate represented by the formula III C1 CH2CH2 N C O III to be converted to an intermediate compound represented by the formula IV EMI7.1 wherein R1 is hydroxy and R2 isEMI7.2 or R1 isEMI7.3 and R2 is hydroxy, and m and n are respectively an integer of 0 to 4 providing that RI , is notEMI7.4 and R2 is not hydroxy when m and n are 0. This reaction is carried out in a polar solvent such as methanol or ethanol, or in dioxane and further in a mixed solvent of water anc one C these solvents at a temperature of 30 to 500C for 1 to 48 hours. Generally, chloroethyl isocyanate is added to a solution of the arinc alcohol while stirring at a predetermined temperate in an amount of from equimolar to an excess of 2 molar, preferably a little more than equimolar amount. The intermediate compound IV is available by evaporating the solvent from the reaction mixture under a reduced pressure. And then, the intermediate compound IV is brought into reaction with nitrous acid which is formed from a metal nitrite such as sodium nitrite and an organic or inorganic acid and represented by the formula V HNO2 V to obtain the present compound. The second reaction is carried out in a polar solvent containing an organic substance.The most convenient solvent is an aqueous acidic solution of a lower carboxylic acid, for instance, formic acid and acetic acid, into which a nitrite such as sodium nitrite is added. The reaction is carried out at 30 to SO0C for 1 to 48 hours. The reaction product is easily extracted from the reaction mixture with an organic solvent sucr as chloroform cr ethyl acetate or with 2 mixed solvent of water and the organic solvent. In addition, the excess amount of metallic ions are removed by using an ionexchange resin. The thus obtained solution is condensed under a reduced pressure to give the isolated product. The product is recrystallized if necessary. Another method for preparing the present compounds is as follows An amino alcohol represented by the formula II is added to a solution of N 2 chloroethyl N nitrosocarbamylazide represented by the formula VI EMI8.1 or p nitrophenyl N 2 chloroethyl N ni trosocarbamate represented by the formula VII EMI8.2 in an alcohol such as isopropyl alcohol or tetrahydrofuran at a temperature of 30 to 500C to be reacted for 1 to 48 hours. The reaction mixture is subjected to extraction with an organic solvent such as chloroform and ethyl acetate to obtain the present compound, which is recrystallized if necessary. The present compound shows anti tumour and anti bacteria activities and a low acute toxicity, as is shown in Examples. Accordingly, the present compound is a useful anti tumour agent as itself or an active ingredient of pharmaceutical composition for treating several tumours such as Sarcoma 180, P 388 lelmia, L 1210 leukemia, Ehrlich s cancer and Yoshida sarcoma on animals, and cancers of the ovary, testis, head and neck, urinary bladder, breast, uterine cervix, and the like. And, the present compound has an anti bacterial activity against gram negative bacteria such as Escherichia coli, and accordingly, is used as an antiinfective disease agent for treating an infection, particularly as an anti bacterial agent for treating a bacterial infection. Furthermore, the present compound may be used as an active ingredient of a pharmaceutical composition for the abovementioned diseases. The present compound can be administered orally or parenterally in the various dosage forms as a composition together with a pharmaceutically acceptable carrier and cr adjuvant. The composition may be in unit dosage form. The dosage form of the composition may be tablet, sugar coated tablet, pill, power, granule, capsule, trouch, solution, suppository and injection. An example of the carrier mentioned above is lactose, saccharose, glucose, sorbitol, mannitol, potato or corn starch, amiropectin, various derivatives of starch and cellulose such as carboxymethylcellulose and hydroxypropylcellulose, gelatin, magnesium stearate, calcium stearate, titanium dioxide, talc, polyvinyl alcohol, polyethylene glycol wax, gum arabic, vegetable oil such as olive oil, peanut oil, sesame oil, paraffin oil, neutral fat base, ethanol, physiological saline solution, sterilized water, glycerol or the like.In the composition, if necessary, tinctorial agent, seasoning agent, thickener, stabilizer, agent for osmoregulation or buffer, that is, the conventional pharmaceutical adjuvant may be used together. The content of the present compound in the pharmaceu tical composition may be varied, however, it is 0.001 85 z by weight, preferably 0.005 609 by weight of the composItion. A dose of the pharmaceutical composItion of t.e present invention is 0.05 to 200 mg, preferably 0.1 to 100 mg per day per one kilogram of the body weight. However the dose of pharmaceutical composition may be varied while mainly depending on condition of a disease of a human or animal. The following Examples illustrate the present invention.PREPARATION OF THE PRESENT COMPOUND EXAMPLE 1 Preparation of 2 methyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol Into 30 ml of methanol, 3.15 g of 2 amino 2 methyl l,3 propanediol was dissolved, and after cooling the solution to O C, 3.6 g of 2 chloroethyl isocyanate was slowly dropped into the cooled solution. After leaving the mixture for one night, the solvent was distilled off from the reaction mixture under a reduced pressure to obtain an oily residue, which was dissolved in a mixed solvent of 15 ml of water and 15 ml of acetic acid. Into the solution under cooling to OOC, 4.12 g of sodium nitrite was added, and the mixture was brought into reaction for one night.Then, the solvent was distilled off from the reaction mixture under a reduced pressure, and the residue was subjected to extraction with 20 ml of water and d0 ml of chloroform followed by two times of extraction with each 40 ml of chlorofor.. After drying the chloroform extract on magnesium sulfate, the extract was condensed under a reduced pressure. The condensate was subjected to chromatography while using 100 c of silica gel to c√èllectthe eluate by a mixed solvent of 95 5 vol of chloroform and methanol, and the eluate was condensed to be a crude product, which was recrystallized from a mixed solvent of ethyl acetate and n exane to obtain 1.0g of 2 methyl 2 3 2 chloroethyl 3 nitrosoureido 1, 3 propanediol. The characteristics of the present compound thus obtained were as follows 1 melting point 55 to 570C 2 elementary analysis C H N theoretical 35.08 5.88 17.53 Experimental 35.30 6.02 17.20 3 infrared absorption IR spectrum shown in Figure 1. EXAMPLE 2 Preparation of 2 ethyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 prosanediol In a similar manner to Example 1 except for the use of 2 amino 2 ethyl 1,3 propanediol in place of 2 amino 2 methyi 1,3 propanediol of Example 1, 2 ethyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol was obtained. The characteristics of the present compound thus obtained were as follows 1 melting point 78 to 810C 2 elementary analysis C z H N theoretical 37.88 6.36 16.56 experimental 37.60 6.32 16.41 3 infrared absorption IRZ spectrum shown in Figure 2. EXAMPLE 3 Preparation of 3 3 2 chloroethyl 3 nitrosoureido 1, 2 propanediol Into a cooled solution of 1.8 g of 3 amino 1,2propanediol dissolved in 20 ml of methanol at 50C, 2.3 g of chloroethyl isocyanate is slowly dropped, and the mixture was left for one night to react. Then the solvent was distilled of from the reaction mixture under a reduced pressure, and the residue was dissolved in a mixed solvent of 15 ml of water and 15 ml of acetic acid. While cooling the solution at 5 C, 4.12 a of sodium nitrite was added to the solution and the mixture was left for one night. Then the solvent was distilled off from the reaction mixture under a reduced pressure, and the residue was subjected to extraction three times with each 50 ml of chloroform after adding 20 ml of water.After drying the chloroform extract on magnesium sulfate, the extract was condensed under a reduced pressure and the condensate was subjected to column chroatgraphy while using 100 g of silica gel to collect the eluate by a foxed solvent of 93 7 vol of chloroform and methanol. By condensing the eluate, a crude product was obtained, which was recrystallized from a mixed solvent of ethyl acetate and n hexane to obtain 1.6 g of 3 3 2 chloroethyl 3 nitrosoureido l,2 propanediol. The characteristics of the present compound thus obtain ed were as follows 1 melting point 46 to 470C 2 elementary analysis H N theoretical 31.93 5.37 18.62 experimental 32.00 5.30 18.30 3 infrared absorption IR spectrum shown in Figure 3. EXAMPLE 4 Preparation of 3 3 2 chloroethyl 3 nitrosoureido 1,2 butanediol Into a cooled solution of 1.9 g of 3 amino 1,2 butanediol dissolved in 20 ml of methanol at OOC, 2.4 g of chloroethyl isocyanate was dropped slowly. After leaving tie reaction mixture for one night, the solvent was distilled off from the mixture under a reduced pressure, and the residue was dissolved in a mixed solvent of 15 ml of water and 15 ml of acetic acid. While cooling the solution to OOC, 4.12 g of sodium nitrite was added to the solution and the reaction mixture was left for one night to react. Then the solvent was removed from the solution under a reduced pressure, and the residue was subjected to extraction three times with each 50 ml of chloroform after adding 20 ml of water. The chloroform extract was dried on magnesium sulfate, condensed under a reduced pressure, and the condensate was subjected to column chromatography while using 100 g of silica gel to collect the eluate by a mixed solvent of 93 7 vol of chloroform and methanol. By condesning the eluate, a crude product was obtained, which was recrystallized from a mixed solvent of ethyl acetate and n hexane to be 1.5 g of 3 3 2 chloroethyl 3nitrosoureido 1,2 butanediol. The characteristics of the present compound thus obtained were as follows 1 melting point 102 to 1040C 2 elementary analysis C 8 H N theoretical 35.07 5.90 17.53 experimental 35.10 5.91 17.50 3 infrared absorption IR spectrum shown in Figure 4. EXAMPLE 5 Preparation of 2 methyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol Into a solution of 20 mmol of N 2 chloroethyl N nitrosocarbarlazide in 10 ml of isopropyl alcohol, a solution of 3.15 g of 2 amino 2 methyl 1,3 propanediol dissolved in 5 rl of isopropyl alcohol was slowly added dropwise at a temperature of 5 C. After stirring the mixture for one night and adjusting the pH of the mixture to be acidic with the addition of 1N H2SO4, the mixture was extracted with 100 ml of chloroform.After washing the chloroform extract with water and drying on sodium sulfate, the extract was condensed under a reduced pressure and the condensate was recrystallized from a mixed solvent of ethyl acetate and n hexane to obtain 1.2 g of 2 methyl 2 t3 2 chloro ethyl 3 nitrosoureido 1,3 propanediol. The characteristics of the present compound thus obtained ere as follows 1 melting point 55 to 57 C 2 elementary analysis C H N theoretical 35.08 5.88 17.53 experimental 35.33 6.01 17.21 3 infrared absorption IR spectrum shown in Figure 5. EXAMPLE 6 Preparation of 3 3 2 chloroethyl 3 nitro soureido 1, 2 propanediol A solution of 1.8 g of 3 amino 1,2 propanediol dissolved in 10 ml of tetrahydrofuran was added to 2 solution of 6.5 g of p nitrophenyl n 2 chloroethyl N nitrosocarbamate dissolved in 10 ml of tetrahydrofuran, and the mixture was stirred for one night at 250C. Then the solvent was distilled off from the mixture under a reduce pressure and the residue was subjected to chromatography by using 100 g of silica gel to collect the eluate wit a mixed solvent of 93 7 vol of chloroform and methanol.The crude product obtained by condens ing the eluate was recrystallized from a mixed solvent of ethyl acetate and n hexane to obtain 3 3 2. Chloroethyl 3 nitro soureido 1,2 propanediol The characteristics cf the present compound thus obtained were as follows 1 melting point 46 to 470C 2 elementary analysis C H z N theoretical 31,93 5.37 18.62 experimental 32.02 5.31 18.31 3 infrared absorption IR spectrum shown in Figure 6. PHARMACOLOGICAL ACTIVITIES OF THE PRESENT COMPOUND EXAMPLE 7 Anti tumor effect against L 1210 leukemia on mouse The successively cultured L 1210 leukemia cells in the as cites of a mouse were transplanted intraperitoneally to a group of the mouse at a rate of 1 x 105 cells animal, and after 24 hours of the transplantation, a solution of each of the present compounds dissolved in an aqueous physiological saline solution was intraperitoneally administered to the group of the mouse once a day for 5 days running. By observing the state of the mice, the average survival days of the administered mice T and those of the control group C were obtained to calculate the prolongation ratio of the mouse s life T C x 100 . The result is shown in Table 1. As seen from Table 1, the prolongation ratio of te life due to the present compounds was larger than that due to the comparative com ound BCKU . TABLE 1 EMI18.1 SEP Compound SEP Dose SEP mg kg SEP Prolongation SEP ratio SEP tb 2 Methyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol SEP 10 SEP 410 tb of SEP the SEP present SEP compound tb 2 Ethyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol SEP 10 SEP 405 tb of SEP the SEP present SEP compound tb 3 3 2 Chloroethyl 3nitrosoureido 1,3 propanediol SEP 10 SEP 420 tb of SEP the SEP present SEP compound tb 3 3 2 Chloroethyl 3nitrosoureido 1,2 butanediol SEP 10 SEP 430 tb of SEP the SEP present SEP compound tb 1,3 Bis 2 chloroethyl 1 nitrosourea SEP BCNU SEP 10 SEP 204 tb of SEP the SEP comparative SEP compound tb EXAMPLE 8 Anti tumour effect against V 7 tumour on a rabbit The cancer cells prepared by extirpating the solid tumour transplated and proliferated in the femoral part of a rabbit, cutting finely and having passed through stainless steel mesh of Tyler standard mesh of 200 were transplanted to the thinner muscle of the femor31 part of a rabbit by using an injector at a rate of 1.5 x 107 cells animal. On the 7th cay and 11th day of the transplantation, the present compound was administered to the transplanted rabbit. The prolongation ratio of the rabbit was calculated by the comparison of the survIval days of the administered rabbits and the not administered control rabbits. The result is shown in Table 2. TABLE 2 EMI20.1 SEP Compound SEP Dose SEP mg kg SEP Prolongation SEP ratio SEP tb 2 Methyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol SEP 10 SEP 205 tb of SEP the SEP present SEP compound tb 2 Ethyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol SEP 10 SEP 230 tb of SEP the SEP present SEP compound tb 3 3 2 Chloroethyl 3nitrosoureido 1,2 propanediol SEP 10 SEP 215 tb of SEP the SEP present SEP compound tb 3 3 2 Chloroethyl 3nitrosoureido 1,2 butanediol SEP 10 SEP 210 tb of SEP the SEP present SEP compound tb 1,3 Bis 2 chloroethyl 1 nitrosourea SEP BCNU SEP 10 SEP 140 tb of SEP the SEP comparative SEP compound tb EXAMPLE 9 Antibacterial activity i A series of 2 times dilution of aqueous solution of each of the present compounds were prepared, and a plate culture medium was prepared by mixing each series with Heart infusion agar culture medium. A strain of Escherichia coli cultured in trypto soy bouIllon at 370C for 18 hours was inoculated on the thus prepared culture medium, and after culturing for 18 hours at 370C, the degree of proliferation of the inoculated bacteria was observed, the inoculum being a plutinum loop full. The results are shown in Table 3. As seen from Table 3, the antabacterial activity of the present compound against Escherichia coli is recognized in vitro. TABLE 3 EMI22.1 SEP Compound SEP Diluted SEP concentration tb SEP 1 SEP 1 2 SEP 1 4 SEP 1 8 tb 2 Methyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol SEP SEP SEP SEP tb of SEP the SEP present SEP compound tb 2 Ethyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol SEP SEP SEP SEP tb of SEP the SEP present SEP compound tb 3 3 2 Chloroethyl 3nitrosoureido 1,2 propanediol SEP SEP SEP SEP tb of SEP the SEP present SEP compound tb 3 3 2 Chloroethyl 3nitrosoureido 1,2 butanediol SEP SEP SEP SEP tb of SEP the SEP present SEP compound tb 1,3 Bis 2 chloroethyl 1 nitrosourea SEP BCNU SEP SEP SEP SEP of SEP the SEP comparative SEP compound tb Notes means the degree of inhibition of thze growth of E. Coli the larger the number of , the larger the inhibition means that no inhibition of the growth of E. coli was observed. ii The effect on the treatment of the infection was tested using mouse as the experimental animal. After 1 to 3 hours of the intraperitoneal inoculation of more than 1 x 105 cells of Escherichia coli to each of the mice, each Cc the present compounds was administered orally or intra peritoneally to the mouse at a dose rate of 1 to 100 mg kg anc the mouse were observed until 7th day after the administration. A survival rate higher than 50 was resulted. Tunis result shows that the present compound is effective in treating the experimental infection. EXAMPLE 10 Acute toxicity Acute toxicity was examined by administering intraperitoneally an aqueous phsiological saline solution in . ich each of the present compounds is dissolved to ICR JCL mouse.The state of the toxicosis was observed for 14 days to obtain the mortality as the time passed by, from which median lethal dose LD50 was calculated according to the graphic method ofLitchfield Wilcoxon. The present compounds showed LD50 larger than 60 rg kg. EXAMPLE 11 Side effects The side effects of the present compounds were examined using JCL ICR mouse as the experimental animal. Each of the present compounds was orally administered to a group of the mouse at a daily dose rate of 10 mg kg once a day for 5 days running, the same procedure being carried out on the other group of the mouse by administering BCNU at the same rate. The results on the nephrotoxicity and the solubility in water were shown in Table 4, As seen from Table 4, in the mice administered withBCNU, albuminurea was observed severely showing the nephrotoxi city of BCNU, while the degree of albuminurea in the animals administered with the present compound was slight. It is clear as seen in Table 4 that the nephrotoxicity and the solubility in water were improved in the present compound as compared toBCNU. TABLE 4 EMI25.1 Compound SEP Nephrotoxicity SEP Solubility SEP in SEP water tb 2 Methyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol SEP SEP good tb of SEP the SEP present SEP compound tb 2 Ethyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol SEP SEP good tb of SEP the SEP present SEP compound tb 3 3 2 Chloroethyl 3nitrosoureido 1,2 propanediol SEP SEP good tb of SEP the SEP present SEP compound tb 3 3 2 Chloroethyl 3nitrosoureido 1,2 butanedoil SEP SEP good tb of SEP the SEP present SEP compound tb 1,3 Bis SEP 2 chloroethyl 1 nitrosourea SEP BCNU SEP SEP not SEP soluble tb of SEP the SEP comparative SEP compound tb Notes means that albuminurea was observed in one to two animals of the total ten animals. means that albuminurea was abserved in eight nine animals of the total ten animals. MANUFACTURE OF THE PHARMACEUTICAL PREPARATIONS EXAiMPLE 12 Manufacture of the tablet 50 Grams of 2 methyl 2 3 2 chloroethyl 3 nitrosoureido 1,3 propanediol was mixed with 300 g of lactose ana 1.5 g of hydroxypropylcellulose, and the mixture was directly pressed to be tablets or after kneading and extruding b a estrig pelletizer to obtain granules, the well dried granules were pressed to be tablets. EXAMPLE 13 Manufacture of the injection 3 3 2 chloroethyl 3 nitrosoureido 1, propanediol was distributed aseptically into glass vials at a rate of 10 mg vial. After removing the remaining smell amount of moisture and bacteria in the vials, the vials were closely sealed. In using, 5 ml of an aqueous 5 by weight solution of glucose or injection was added to the content of each vial to prepare the injection.